SCLX icon

Scilex Holding

17.29 USD
-0.41
2.32%
At close Updated Dec 10, 4:00 PM EST
Pre-market
After hours
17.63
+0.34
1.97%
1 day
-2.32%
5 days
-13.16%
1 month
-5.78%
3 months
-32.01%
6 months
186.73%
Year to date
13.23%
1 year
-14.02%
5 years
-94.98%
10 years
-94.98%
 

About: Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Employees: 30

0
Funds holding %
of 7,505 funds
Analysts bullish %
0
Positive news %
Price charts implemented using Lightweight Charts™